Human JAM-B/VE-JAM Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB10741
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Phe29-Asn236 (predicted)
Accession # P57087
Specificity
Clonality
Host
Isotype
Endotoxin Level
Scientific Data Images for Human JAM-B/VE-JAM Antibody
Cell Adhesion Mediated by JAM‑B/VE‑JAM and Neutral-ization by Human JAM‑B/ VE‑JAM Antibody.
Recombinant Human JAM-B/VE-JAM Fc Chimera (Catalog # 1074-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Human JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB10741). The ND50 is typically 0.6-3.0 µg/mL.Applications for Human JAM-B/VE-JAM Antibody
Western Blot
Sample: Recombinant Human JAM-B/VE-JAM Fc Chimera (Catalog # 1074-VJ)
Neutralization
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: JAM-B/VE-JAM
The family of juctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial cells or epithelial cells. Some family members are also found on blood leukocytes and platelets. JAM-B, alternatively named vascular endothelial JAM (VE-JAM), is expressed prominently on high endothelial venules of lymphoid organs where it is localized to the intercellular boundaries of high endothelial cells. It is also expressed on the endothelium of a variety of non-lymphoid organs, especially the heart and placenta (3, 5). Human JAM-B cDNA predicts a 298 amino acid (aa) precursor protein with a putative 28 aa signal peptide, a 209 aa extracellular region containing two Ig domains, a 23 aa transmembrane domain and a 38 aa cytoplasmic domain containing a PDZ-binding motif and a PKC phosphorylation site. Human JAM-B shares approximately 79% aa sequence homology with its mouse homologue. It also shares approximately 35% aa sequence homology with human JAM-A or JAM-C. JAM-B exhibits homotypic interactions, as well as heterotypic interactions with JAM-C, but not JAM-A (4, 5, 7). It is also a ligand for the Integrin alpha4 beta1. However, the JAM-B/ alpha4 beta1 interaction is facilitated only after prior adhesion of JAM-B to JAM-C (6). Through its heterotypic interactions with JAM-C, JAM-B is an adhesive ligand for T, NK, and dendritic cells, and may play a role in regulating leukocyte transmigration (5).
The nomenclature used for the JAM family proteins is confusing. VE-JAM has been referred in the literature variously as JAM-B or JAM-3. Until further clarification, R&D Systems has adopted the nomenclature where both mouse and human VE-JAM are referred to as JAM-B.
References
- Chavakis, T. et al. (2003) Thromb. Haemost. 89:13.
- Aurand-Lions, M. et al. (2001) Blood 98:3699.
- Palmeri, A. et al. (2000) J. Biol. Chem. 275:19139.
- Cunnigham, S. et al. (2000) J. Biol. Chem. 275:34750.
- Liang, T. et al. (2002) J. Immunol. 168:1618.
- Cunningham, A. et al. (2002) J Biol. Chem. 277:27589.
- Arrate, M. et al. (2001) J. Biol. Chem. 276:45826.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional JAM-B/VE-JAM Products
Product Documents for Human JAM-B/VE-JAM Antibody
Product Specific Notices for Human JAM-B/VE-JAM Antibody
For research use only